Products
Crisaborole was approved in the United States in 2016 as an ointment (Eucrisa, 2%). Crisaborole is not currently registered in many countries.
Structure and properties
Crisaborole (C14H10BNO3, Mr = 251.0 g/mol) is a low molecular weight boron compound with a nonsteroidal structure. It belongs to the phenoxybenzoxaboroles. Due to its small size, the compound can penetrate into the upper layers of the skin.
Effects
Crisaborole has anti-inflammatory properties. The effects are based on the inhibition of phosphodiesterase-4 (PDE-4), which leads to an increase in intracellular cAMP. The result is reduced formation of proinflammatory cytokines.
Indications
For the treatment of atopic dermatitis (neurodermatitis).
Dosage
According to the professional information. The ointment is applied locally twice a day (morning and evening).
Contraindications
Crisaborole is contraindicated in case of hypersensitivity. Full precautions can be found in the drug label.
Adverse Effects
The most common potential adverse effects include pain (a burning and stinging sensation) at the application site. Hypersensitivity reactions have been reported.